Last checked at 21 Jun 2017 14:53
For immediate release | 21 June 2017 |
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Application for block admission
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that it has today applied for a block admission for a further 25,000,000 ordinary shares of 1p each in the Company ("Ordinary Shares") to be admitted to trading on AIM (the "Block Admission"). The Block Admission will be used to facilitate the admission of shares to trading following the exercise of options granted under the following employee share schemes:
· The Alliance Pharma plc Approved Share Option Plan 2005 (up to 2,248,922 shares);
· The Alliance Pharma plc Share Option Plan 2006 (up to 19,461,225 shares); and
· The Alliance Pharma plc Company Share Option Plan 2015 (up to 3,289,853 shares).
It is expected that the Block Admission will become effective in the Ordinary Shares on 28 June 2017.
The Company will make six-monthly announcements of the utilisation of the Block Admission, in line with its obligations under AIM Rule 29.
New Ordinary Shares issued following option exercises and admitted to trading under the Block Admission will rank pari passu in all respects with the existing Ordinary Shares.
At the time of this application, Alliance has 474,307,589 Ordinary Shares in issue.
For further information:
Alliance Pharma plc | + 44 (0) 1249 466966 |
John Dawson, Chief Executive Andrew Franklin, Chief Financial Officer | |
Rob Bellhouse, Company Secretary | |
www.alliancepharma.co.uk | |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court / Sophie Cowles | |
Numis Securities Limited | + 44 (0) 20 7260 1000 |
Nominated Adviser: Michael Meade / Freddie Barnfield | |
Corporate Broking: James Black / Toby Adcock |
Notes to editors:
About Alliance Pharma
Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors. Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.